Updates on Lumina Probiotic

Follow-up to Scott's Dec-2024 Lumina (anti-cavity GM bacterium) FAQ, prompted by the $20k->$250 price drop plus Hanania/Cremieux endorsements and commenter corrections. Reconciles the conflicting FDA-trial histories, walks back the rat-study 'complete cure' claim, reports the 4-of-6 colonization retest, flags a new ALDH/oral-cancer concern, and -- the core -- gives a numerate probability breakdown of Lumina's value and a careful 'I don't endorse it, but +EV testing for society is not +EV for every individual' stance. Honest, calibrated, non-hype.

Quality 64 · Strong. Strong: a competent, numerate, intellectually-honest update that models good calibration (explicit probability estimates) and the file-drawer/+EV-testing argument, but it is a secondary follow-up that mostly reconciles corrections rather than advancing a new thesis -- squarely mid-Strong, not Excellent.

Claude’s paradigm shift 32 · Slight. Slight/low: an update post with little novelty; the 'test cheaply outside the FDA' and file-drawer framings restate Scott's standing positions.

Real-world impact 2 · Minor. Minor/within-discourse: the Lumina saga has real customers and Scott's coverage measurably drives interest, but this particular update's marginal material impact is small and speculative.